Last updated: July 30, 2026
BELEODAQ (belinostat) is a late-stage oncology asset with a narrow FDA-approved indication set (per its label), a largely small-molecule patent landscape, and an exclusivity profile that is already largely mature. Investment-relevant outcomes hinge on (1) whether any Orange Book-listed patents remain enforceable in key geographies, (2) the presence and posture of any ANDA/Paragraph IV challenges for belinostat, and (3) follow-on formulation or method-of-use IP that can extend exclusivity beyond the original composition-of-matter core.
What patents protect BELEODAQ (belinostat) in the US, and how many are still enforceable?
Answer (US): BELEODAQ is protected by a small-molecule patent estate typical for belinostat, with enforceability determined by Orange Book listings (active patents covering drug substance or drug product) and their expiration dates. The enforceability window is driven by the last-expiring US patent (plus any Hatch-Waxman exclusivity) rather than by early filings.
What is the primary IP for belinostat?
Most small-molecule oncology programs share the same hierarchy:
- Composition of matter (drug substance): core belinostat chemistry coverage.
- Composition of product (drug formulation): tablets/capsules or solid oral formulations, stability, polymorph, or process-related claims.
- Methods of use: dosing regimens and patient selection language tied to specific indications.
For an investment stance, the highest-impact questions are whether Orange Book still lists any drug substance patents and whether any drug product/formulation patents remain active that can block at-launch generics.
How to count the patent estate: drug substance vs drug product vs method-of-use
Investment screens should separate patents into three buckets:
- Drug substance patents (most durable leverage against generics).
- Drug product patents (can block “true” generic substitution if claim coverage is specific).
- Method-of-use patents (rarely stop ANDAs at approval unless label includes claimed uses; still relevant for US litigation and label design).
What are the key US patent expirations to monitor?
An accurate expiration map requires direct Orange Book listing data for BELEODAQ. Without verified listing and claim term details, an expiration-by-patent table cannot be constructed to a litigation-grade standard.
When does BELEODAQ lose exclusivity in the US, and what are the generic entry timelines?
Answer (US): BELEODAQ’s practical exclusivity timeline is determined by Orange Book active patents plus any statutory exclusivity (NCE and/or other FDA exclusivities tied to initial approval). Once the last enforceable patent term or exclusivity expires, generic entry generally becomes available via ANDA, subject to label carve-outs for any method-of-use or remaining product-specific patents.
What exclusivity drives ANDA timing?
- Statutory exclusivity: governs the earliest time generic sponsors can file and, in some cases, the earliest approval time.
- Patent barriers: govern whether a generic must wait for expiration or can enter “at risk” if it files Paragraph IV and challenges a listed patent.
- Settlement agreements: can shift effective entry date even if patents are weak.
Generic launch scenario framework (US)
A practical investment model uses three scenarios:
- Base case: no material late-formulation IP and no meaningful Paragraph IV wave; generic entry occurs when last listed patent expires (or at the settlement date if later).
- IP resilience case: late-expiring formulation or method-of-use patents prevent full label substitution; generic entry occurs but with label limitations and lower competitive substitution.
- IP erosion case: early settlements or patent invalidation reduce barriers; generic entry accelerates beyond base case.
A litigation-grade timeline cannot be published here without verified Orange Book, court dockets, and settlement terms.
How many patents cover belinostat, and which companies own and assert the BELEODAQ estate?
Answer: The ownership/assignee set and enforcement activity are defined by the Orange Book patent list and by court filings in any US district court actions. A complete, high-confidence identification of assignees, asserted patents, and challengers requires direct patent-list and litigation docket evidence.
What investors should track: assignee concentration and challenger patterns
Investment signals come from:
- Concentration of assignees: single-company control suggests consistent prosecution and enforcement strategy.
- Challenger repetition: repeated Paragraph IV filers suggest market pull and confidence in invalidity/unenforceability arguments.
- Trial outcomes: early dispositive rulings shape the likelihood of sustained enforcement or retreat.
Which jurisdictions matter beyond the US?
For small-molecule oncology drugs, the highest economic relevance typically follows:
- US (ANDA and litigation leverage)
- EU (national validations and parallel generic actions)
- UK/Canada/Australia (varies by portfolio strategy)
A correct jurisdiction map needs the verified family of belinostat patents and whether national phase or supplementary protection certificates (SPCs) exist.
What is the Orange Book status of BELEODAQ (belinostat), and which patents are listed?
Answer: Orange Book status is the primary source for enforceability. BELEODAQ’s Orange Book listing status needs to be checked to identify:
- listed patent numbers
- patent expiration dates
- dosage form and strength covered
- submission type (drug substance vs drug product)
- any patent exclusivity periods relevant to ANDA timing
A litigation-grade Orange Book snapshot cannot be generated here without the listing dataset.
What generic entry risks exist for BELEODAQ if Paragraph IV ANDAs are filed?
Answer: The generic entry risk is high if there are:
- active listed patents with short remaining terms
- prior Paragraph IV notices indicating likely challenges to the key patents
- settlement agreements that permit earlier-than-statutory entry
Conversely, risk is lower if:
- major patents remain in force with ongoing infringement proceedings
- settlements delay generic entry
- remaining patents are formulation- or method-of-use-specific in ways that limit generic substitution
What Paragraph IV patterns would change the investment view?
- Multiple challengers filing against the same key patent suggests confident invalidity arguments.
- One challenger and early settlement suggests a cost-of-entry strategy rather than a full IP win.
- Trial loss by a challenger signals stronger enforceability and can deter subsequent entrants.
How investors should model “at-risk” entry
At-risk entry affects near-term revenue drawdown:
- Lower-priced generics can start revenue pressure once approved
- Label carve-outs can preserve some branded uptake
- Pharmacy substitution depends on therapeutically equivalent labeling language and payer formularies
A quantitative revenue exposure model requires observed price, substitution rates, and timing assumptions grounded in the actual approval/entry events.
What patent litigation affects BELEODAQ (belinostat), and what is the posture of current cases?
Answer: US patent litigation risk is governed by the existence and status of:
- infringement suits filed after Paragraph IV notices
- counterclaims for invalidity and non-infringement
- court rulings affecting injunction scope or patent status
A complete litigation posture table requires docket-level confirmation of case numbers, parties, asserted patents, claim construction, and outcomes.
What to track in court filings: injunction risk and claim scope
Investment-relevant milestones:
- Markman/claim construction outcomes
- stay or lifting of FDA approval triggers
- final judgment validity findings or settlement termination conditions
- appellate timelines that extend enforceability in practice
What formulations and dosage forms are protected by BELEODAQ patents?
Answer: BELEODAQ is a solid oral drug. Investors should assess whether patents cover:
- specific strengths
- excipient systems
- manufacturing processes and controls
- stability or polymorph-specific claims
Formulation IP can materially affect generic launch competitiveness if claims are drafted to require specific excipients, dissolution profiles, or manufacturing steps.
Dosage form design barriers typical for solid oral belinostat
Investors typically look for:
- patent coverage over solid-state forms (polymorph, hydrate)
- process patents tied to crystallization conditions
- impurity control and specification patents
No claim-level formulation map is published here due to the lack of verified patent documents and claim charts.
How does BELEODAQ compare with other belinostat-adjacent oncology options on IP and commercial attractiveness?
Answer: BELEODAQ’s competitive attractiveness in investment terms usually depends on:
- whether alternative HDAC inhibitors have stronger patent walls or faster growth
- whether payers and guidelines favor belinostat for its labeled population versus newer competitors
- whether belinostat has meaningful off-label uptake sustained by clinical evidence
A relative comparison requires the branded and pipeline landscape for HDAC inhibition and the revenue and label status of comparable agents.
Is BELEODAQ eligible for biosimilar substitution, and what does that mean for competition?
Answer: BELEODAQ is a small molecule and is not eligible for biosimilar substitution. Competition is via generic small-molecule ANDAs (and potentially authorized generics) rather than biosimilars.
Key investment scenario: revenue exposure vs IP erosion vs entry timing
Answer: With BELEODAQ being a mature small-molecule asset, the highest-risk investment vector is generic erosion if enforceable US patents are limited in duration or already expired, or if settlement and Paragraph IV events allow earlier entry.
Base case vs upside vs downside
- Base case (stable to modest erosion):
- generic entry occurs at or near the last patent expiration or post-settlement effective date
- label limitations reduce substitution speed
- Downside (rapid erosion):
- multiple Paragraph IV challenges and favorable early outcomes
- settlement enables earlier effective date with broad label parity
- Upside (patent resilience or reformulation protection):
- late-expiring formulation or method-of-use patents keep substitution constrained
- authorized competitor strategy preserves some branded pricing
What drives valuation: IP duration, likelihood of carve-outs, and commercial survivability
For valuation, investors should weight:
- remaining years of active enforceable patents (last-expiring listed patent)
- evidence of generic filing interest (Paragraph IV notices)
- settlement history and typical entry date shifts
- branded remaining profitability and payer dynamics post-competition
A numeric valuation cannot be produced without verified patent timelines, FDA/Orange Book listings, and any known generic entry or settlement dates.
Key Takeaways
- BELEODAQ (belinostat) is a small-molecule oncology product; competition risk is generic ANDA entry, not biosimilars.
- Investment outcomes depend on Orange Book active patents, the last-expiring enforceable patent in each relevant territory, and any Paragraph IV notices or litigation affecting effective entry dates.
- A litigation-grade exclusivity and generic risk map requires Orange Book listing verification plus docket-level litigation status; without those verified inputs, a precise expiration and case-by-case timeline cannot be stated here.
FAQs
- What is the Orange Book patent list for BELEODAQ (belinostat), and which patents cover the drug substance versus drug product?
- Do any BELEODAQ patents cover method-of-use claims that could force generic label carve-outs in the US?
- Have any Paragraph IV ANDAs been filed for belinostat, and what entry timelines do they imply?
- What types of formulation patents (polymorph, excipients, process) most often block generic substitution for solid oral oncology drugs like belinostat?
- How should investors model BELEODAQ revenue erosion after generic approval given likely payer substitution behavior and label scope?
References
- US Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. (Orange Book database).
- US FDA. Hatch-Waxman Drug Patent Certification and Related Regulations (Paragraph IV notice framework).
- FDA. Drug Approval and Exclusivity Documentation (NCE and other exclusivity overview).
